Company
Headquarters: Zhuhai, China
Employees: 2,280
CN¥24.22 Billion
CNY as of Jan. 1, 2025
US$3.32 Billion
| Company | Market Cap (USD) |
|---|---|
| Abbott | $213.72 B |
| Stryker | $150.01 B |
| Boston Scientific Corporation | $149.80 B |
| Medtronic | $114.44 B |
| Shenzhen Mindray Bio-Medical Electronics Co. Ltd | $47.37 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Jafron Biomedical Co.,Ltd. engages in the research, development, production, and marketing of biological materials and medical devices in China. It offers solutions for kidney, liver, critical, and rheumatism diseases, as well as poisoning; adsorption products and blood purification machines; and other products, such as single use arteriovenous puncture, hemodialysis online dry powder bags/cylinders, disinfectants, hemodialysis concentrates, and medical adsorbable suture with needles. The company offers its products in Germany, Italy, Turkey, Thailand, Vietnam, the Philippines, South Africa, Kenya, Chile, Peru, and the United Arab Emirates. Jafron Biomedical Co.,Ltd. was founded in 1989 and is based in Zhuhai, China.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
| Last Financial Reports Date | Sept. 30, 2024 |
| Revenue TTM | CN¥2.63 B |
| EBITDA | CN¥1.07 B |
| Gross Profit TTM | CN¥1.54 B |
| Profit Margin | 30.56% |
| Operating Margin | 41.78% |
| Quarterly Revenue Growth | 47.70% |
Jafron Biomedical Co.,Ltd. has the following listings and related stock indices.
Stock: SZSE: 300529 wb_incandescent